Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för HMN-214. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2023-01-29

Identification of Inhibitors of Tubulin Polymerization Using a CRISPR-Edited Cell Line with Endogenous Fluorescent Tagging of β-Tubulin and Histone H1.

Khachatryan H, Olszowy B, Barrero CA, Gordon J, Perez-Leal O.

Biomolecules · research-article; journal article; research support, n.i.h., extramural · DOI 10.3390/biom13020249

Bibliografisk träff 2022-04-24

Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth.

Chilamakuri R, Rouse DC, Agarwal S.

Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph15050523

Bibliografisk träff 2015-02-11

Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression.

Christensen MD, Elmer JJ, Eaton S, Gonzalez-Malerva L, LaBaer J, Rege K.

J Control Release · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jconrel.2015.01.036

Bibliografisk träff 2009-05-27

Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.

Schöffski P.

Oncologist · review; journal article · DOI 10.1634/theoncologist.2009-0010

Bibliografisk träff 2006-09-01

A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.

Garland LL, Taylor C, Pilkington DL, Cohen JL, Von Hoff DD.

Clin Cancer Res · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-06-0214

Bibliografisk träff 2004-10-01

Gateways to clinical trials.

Bayés M, Rabasseda X, Prous JR.

Methods Find Exp Clin Pharmacol · bibliography; journal article

Bibliografisk träff 2003-11-01

In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176.

Takagi M, Honmura T, Watanabe S, Yamaguchi R, Nogawa M, Nishimura I, Katoh F, Matsuda M, Hidaka H.

Invest New Drugs · comparative study; journal article · DOI 10.1023/a:1026282716250

Bibliografisk träff 2003-10-01

HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y.

Tanaka H, Ohshima N, Ikenoya M, Komori K, Katoh F, Hidaka H.

Cancer Res · research support, non-u.s. gov't; journal article